Top Banner
57

The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Apr 24, 2018

Download

Documents

doanhuong
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity
Page 2: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity
Page 3: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity
Page 4: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Teeth loss

Page 5: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Pattern of bone resorption after extraction

2/ 3 in

first 3

months

50% in

1st

year

Reich KM, Huber CD, Lippnig WR, Um C, Watzek G, Tangl S . (2011, 17) . Atrophy of Residual Alveolar Ridge following

tooth loss in an historical population , Oral Diseases, 17, 33-44.

Page 6: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Vertical Alveolar deficiency

3 dimensional Defect (3D bone reconstruction)

The larger the defect the

greater is the tension

Soft tissue tension increase

resorption of graft

Wound Dehiescence(infection, loss of graft)

Le, B., Rohrer, M. D., & Prassad, H. S. (2010, 02). Screw “Tent-Pole” Grafting Technique for Reconstruction of Large

Vertical Alveolar Ridge Defects Using Human Mineralized Allograft for Implant Site Preparation. Journal of Oral and

Maxillofacial Surgery, 68(2), 428-435.

Page 7: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Management of vertical alveolar ridge deficiency

Donor site morbidity

Higher rate of bone resorption

Wound Dehiscence

Zhang, Z. (2011, 12). Bone regeneration by stem cell and tissue engineering in oral

and maxillofacial region. Front. Med. Frontiers of Medicine, 5(4), 401-413.

Page 8: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stem Cell Based Alveolar

Regeneration

Expanded

MSCs

Page 9: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stem Cell Based Alveolar Regeneration

Cells

Scaffold

Growth Factor

Cells Scaffold

Growth

Factor

Mechanical

Environment

Nie e Nie, H., Lee, C. H., Tan, J., Lu, C., Mendelson, A., Chen, M., . . . Mao, J. J. (2012, 03). Musculoskeletal tissue

engineering by endogenous stem/progenitor cells. Cell Tissue Res Cell and Tissue Research, 347(3), 665-676.

t al., 2012 9

Page 10: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stem Cell Based Alveolar Regeneration

Page 11: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Cells

Stable with extended

passaging

Ease of isolationMultipotency

Rapid expansion

Egusa, H., Sonoyama, W., Nishimura, M., Atsuta, I., & Akiyama, K. (2012, 10). Stem cells in dentistry – Part II: Clinical

applications. Journal of Prosthodontic Research, 56(4), 229-248.

Page 12: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Cells- Proliferation

& differentiation - Migration & chemotaxix-Provide cell attachment- Maintain phenotye

Tissue -Biocompatible-Biodegradable - Mechanical

strength before degradation

-Angiogenesis & vasculogenesis- Hydrophillic

Surgeon -cost effective

- easily handled

-available in relevant

quantities

Bose, S., Roy, M., & Bandyopadhyay, A. (2012, 10). Recent advances in bone tissue engineering scaffolds. Trends in

Biotechnology, 30(10), 546-554.

Page 13: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Fibrin Scaffold in Bone tissue Engineering

BM-MSCs in treatment of articular cartilage defects.

BM- MSCs in treatment of alveolar bone defects in

rats.

FG PRP PRF

Dohan, D. M., Choukroun, J., Diss, A., Dohan, S. L., Dohan, A. J., Mouhyi, J., & Gogly, B. (2006, 03). Platelet-rich fibrin (PRF): A second-

generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and

Endodontology, 101(3).

Page 14: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

PRF in Bone Tissue Engineering

- Ehrenfest, D. M., Diss, A., Odin, G., Doglioli, P., Hippolyte, M., & Charrier, J. (2009, 09). In vitro effects of Choukroun's PRF (platelet-rich

fibrin) on human gingival fibroblasts, dermal prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures. Oral Surgery,

Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 108(3), 341-352.

- Ehrenfest, D. M., Doglioli, P., Peppo, G. M., Corso, M. D., & Charrier, J. (2010, 03). Choukroun's platelet-rich fibrin (PRF) stimulates in vitro

proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Archives of Oral Biology, 55(3), 185-194.

- Wu, C., Lee, S., Tsai, C., Lu, K., Zhao, J., & Chang, Y. (2012, 05). Platelet-rich fibrin increases cell attachment, proliferation and collagen-

related protein expression of human osteoblasts. Australian Dental Journal, 57(2), 207-212.

Stimulation of cellular adhesion and Proliferation of human

gingival fibroblast, dermal prekeratinocyte, preadipocyte and

maxillofacial osteoblast and also osteoblastic differentiation

Dose dependant stimulation of Proliferation & differentiation of

BM-MSCs

Stimulate cellular adhesion and proleferation of rat osteoblasts,

human osteoblasts, human periodontal ligament fibroblasts, and

human pulp fibroblasts.

Page 15: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity
Page 16: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Aim Of The Study

(PRF+ MSCs)(PRF+ MSCs +Bi- Phasic

Ca- Ph)

Pattern of Bone Formation

Page 17: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Materials & Methods

Page 18: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

12 – 24 months25- 40 Kg Weight

3 vertical alveolar ridge

defects

10 dogs

Page 19: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stem Cell Isolation, Characterization

and expansion

Stage II

Animal Scarify

Stage I

A- In-Vivo

B- In-Vitro

Defect induction

Gingival harvesting

Augmentation

Procedures

Page 20: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

A- In- Vivo

Stage I

(Defect Induction )

Page 21: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stage I

(Defect Induction )

Page 22: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stage I

(Defect Induction )

Page 23: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

4 Weeks

Stage I

(Defect Induction )

Page 24: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stage I

Gingival Harvesting

Page 25: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Tissue Engineering Laboratory

Page 26: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Stage II

Augmentation Procedures

Group I (PRF + MSCs)

Group II (PRF + MSCs + Bi-phasic

Ca- Ph block)

Group III (PRF + Bi- phasic

Ca- Ph block)

Page 27: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

PRF

Scaffold Preparation

Page 28: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Augmentation Procedures

Page 29: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Mesh Fixation

Page 30: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group I

(PRF+ MSCs)

Page 31: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group II

(PRF+ Bi- Phasic Ca- Ph +

MSCs)

Group III

(PRF+ Bi- Phasic Ca- Ph)

Page 32: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group II

(PRF+ Bi- Phasic Ca- Ph +

MSCs)

Group III

(PRF+ Bi- Phasic Ca- Ph)

Page 33: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity
Page 34: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Results

Page 35: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

In-vitro

MSCs in Culture

Multi-lineage

Differentiation

Cell Surface Marker

Expression

Osteogenic

Chondrogenic

Page 36: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

MSCs in Culture

Day 0Day 14

Day 7

Page 37: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Cell Surface Marker Expression

Page 38: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Multi-lineage Differentiation

OsteoblasticDifferentiation

ChondrogenicDifferentiation

Page 39: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

In-vivo

Histology

H & E

Histomorphometry

Bone

Matrix

Mature

Bone

Histochemical

(Masson Trichrome)

Page 40: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Bone formation

in center

Bone Interface

Bone

Trabeculae

Reversal

LinesOsteocytes Osteoclasts

Histological Results

H & E

Page 41: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group I

Bone formation in

center Bone interface

Page 42: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Bone

Trabeculae

Reversal

LinesOsteocytes Osteoclasts

Group I

Page 43: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group II

Bone formation in

center Bone interface

Page 44: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Bone

Trabeculae

Reversal

LinesOsteocytes Osteoclasts

Group II

Page 45: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group III

Bone formation in

center Bone interface

Page 46: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Bone

Trabeculae

Reversal

LinesOsteocytes Osteoclasts

Group III

Page 47: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Histomorphometric Results

Area percent of Mature Bone

Page 48: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

0.00

10.00

20.00

30.00

40.00

50.00

60.00

70.00

80.00

90.00

Gp 1 Gp2 Gp3

75.98

81.91

35.35

Mean area percent of Mature Bone

Page 49: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Histochemical Results

Group I

Page 50: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group II

Page 51: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Group III

Page 52: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Histomorphometric Results

Area percent of Bone Matrix

Page 53: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

0.00

10.00

20.00

30.00

40.00

50.00

60.00

Gp 1 Gp2 Gp3

12.56

50.17

10.60

Perc

ent

Mean area percent of Bone Matrix

Page 54: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Conclusion

Page 55: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

PRF membranes loaded with MSCs could induce early

bone formation and maturation in vertical alveolar defects.

PRF couldn't support osteogensis process in vertical

alveolar ridge defects till complete bone formation and

restoration of the whole bone volume.

The combined use of Bi-phasic calcium phosphate block

together with PRF loaded with MSCs is superior to single

use of PRF loaded with MSCs in treatment of vertical

alveolar ridge defects.

The combined use of Bi-phasic calcium phosphate block

together with MSCs loaded PRF yields promising results in

treatment of vertical alveolar ridge defects

Page 56: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Recommendation

Larger sample size with longer period of follow up.

Radiographic assessment.

Page 57: The Use of Expanded Mesenchymal Stem Cells (MSCs ...scholar.cu.edu.eg/ashrafseida/files/ph.d._presentation.pdfManagement of vertical alveolar ridge deficiency Donor site morbidity

Thank You